Key Takeaways
- Revlimid windfall reinvested, not banked: A onetime ~INR50 crores supplier success payment and a sharp R&D ramp pushed gross margins down, but management is deliberately channeling surplus cash into pipeline build-out rather than optimizing near-term profitability.
- Subsidiaries are the declared future: Canada and Brazil together contributed ~INR555 crores in revenue, and new entities in Colombia and Indonesia are being set up. Management stated plainly, "The future of the business is the subs."
- Base business profitability is modest: Ex-Revlimid, the core business generates only INR40–50 crores in quarterly PAT. Management believes niche, hard-to-do generics are the only path to dramatic growth, conceding that in multi-generic markets "there's no money."
- R&D spend is set to jump 50%: Management wants to spend more than INR300 crores on R&D this year, up from ~INR200 crores, funding bio studies and exhibit batches across the U.S., Canada, and Brazil to build a pipeline of complex generics.
- What to watch next quarter: The pace of Revlimid volume sell-through (75% of the current allocation remains), whether the Agro business liquidates INR100–110 crores of inventory in the Kharif season, and any closure on the long-awaited domestic acquisition.
Revlimid: The Quarter's Defining Dynamic
- Volume cycle reset: The first 12-month allocation from last year is fully sold. The company is now selling into its current-year allocation, with 25% sold from the launch date and the remaining 75% expected to move in the June quarter, with some spill into September.
- Margin impact was material: A pre-agreed success payment of INR50 crores to an Indian raw material supplier hit consumption this quarter, contributing to the sharp gross margin decline. Management declined to identify the specific product or agreement when pressed.
- Volume share already stepped up: The increased monthly volume share is already in effect and will meaningfully play out in Q1 and Q2. Management would not quantify the year-on-year volume improvement beyond saying, "It will be better than last year, and our earnings, hopefully will be better as well."
- Competitive sensitivity is extreme: Management refused to disclose Revlimid's top-line or bottom-line contribution, future volume assumptions, or pricing scenarios, calling it "competitive information" and declining to predict the pricing environment even a few years out.
Rajeev Nannapaneni: "I can't predict the pricing environment a few years down the line. I can't answer that question. Sorry."
Subsidiaries & International Expansion
- Canada and Brazil delivered: The two main subsidiaries contributed ~INR555 crores in revenue, with Canada doing ~CAD 4 crore and Brazil ~2 crore-odd. Growth from INR80 crores to INR117–118 crores was driven by new launches, especially apixaban in Brazil, and good tender orders in Canada.
- New markets being seeded: Subsidiaries are being set up in Colombia and Indonesia, and management is looking to buy an asset in the U.K. The strategy is to globalize the R&D pipeline and extend it to multiple markets simultaneously.
- DASH is a front-end investment, not yet a contributor: The U.S. front-end acquisition carried INR50 crores in goodwill and is not making money now. Management expects the benefit of owning the front end to materialize in the next 1–2 years, with some complex generics routed through partnerships and some through the subsidiary.
- Filing cadence is the growth engine: The three key markets are the U.S., Canada, and Brazil, each targeted for 8 to 10 new product filings. Subsidiaries have already filed about 7 to 8 products, with litigation ongoing. Management expects 15% to 20% growth from subs in the coming year.
Rajeev Nannapaneni: "The future of the business is the subs."
R&D & Pipeline Strategy
- Surplus is being deliberately deployed into R&D: Management framed the decision as a direct answer to the question of what to do with surplus cash, choosing to spend on bio studies and new exhibit batches to strengthen the pipeline rather than let margins expand. R&D was ~7–8% of revenues this quarter, with guidance of about 10% for the coming year.
- The ambition is a 50% spending increase: Management wants to spend more than INR300 crores on R&D, up from roughly INR200 crores last year, though the final number depends on cash flow. Spending is spread across all major markets, not just the U.S.
- Complex generics are the thesis: The company is targeting another 8 to 10 first-to-file or niche/hard-to-do generics. Management acknowledged the inherent unpredictability: litigation-driven timelines mean launches cannot be dated, and the objective is to file 7–10 such products hoping 3–4 succeed.
- Two FTF achievements disclosed: Two sole first-to-files were achieved in the last 12 months. One is a joint venture with Alembic (olaparib/Lynparza), and semaglutide (Ozempic) has been filed with Mylan, though management refused to confirm FTF status or timeline for semaglutide, citing ongoing patent litigation.
Rajeev Nannapaneni: "I think the question that NATCO is facing is -- what do we do with our surplus, right? And I think I have decided that I'll use the surplus for spending money on bio studies and new exhibit batches."
Base Business & Profitability
- The base business is steady but small: Ex-Revlimid, the base business generates PAT of around INR40–50 crores per quarter, the same range as before. Domestic formulations ran at a ~INR100 crores quarterly run rate, with the year-on-year decline explained by a onetime return of a COVID product.
- Management is candid about the ceiling: In hypercompetitive markets with 15 generics, "there's no money." Base business alone yields meager earnings and will not change the needle dramatically; niche products are the only path to step-change growth.
- The path to INR100 crores quarterly profitability: To reach that level from the current INR40–50 crores, Agro needs to hit INR150–200 crores, domestic must grow 15–20%, and subs must grow 15–20%.
- API business is lumpy but guided up: API degrew slightly in FY23 but posted ~70% QoQ growth in Q4 as confirmed customer orders landed, with some Q3 supply delays shifting into Q4. Internal projection is 20–25% growth this year.
Rajeev Nannapaneni: "In a multi-generic source, there's no money. It's the honest truth."
Agro & Crop Protection
- CTPR launch is the strategic beachhead: The launch is about 15% of the whole Agro business and sets the base for launching other products. Approval came late, but everything is now set up, and the full value of CTPR is expected to be realized this financial year.
- Inventory liquidation is a near-term catalyst: Management expects to liquidate ~INR100–110 crores of inventory in the Kharif season across the June and September quarters, with traction described as very good.
- Pipeline of first-time indigenized products: A list of 5–6 products is expected to launch in the next 2 years, all under review in the CAB. Some are litigation-driven, some are not. Management will disclose details in the next 12 months as launches approach.
- Financial trajectory improving: Agro was losing INR45–50 crores a year; this year the loss will be lower because of the launch and full-year advantages. The projection is INR150-plus crores this year, targeting INR200 crores, with an internal goal of growing crop protection to about 10% of total sales.
Domestic Business & Capital Allocation
- Organic growth plus acquisition ambition: Domestic business is expected to grow 8–10% organically, with an internal target of 20–25% including acquisitions. Management is looking at strategic opportunities with cash on the books and hopes to close something this year, while candidly acknowledging two years of undelivered promises on this front.
- Buyback completed: The buyback of ~35 lakh shares closed in April–May, reducing equity from INR18.25 crores to INR17.91 crores, roughly 2% of equity.
- India launch cadence: The company needs to launch about 10 products in the domestic market.
Rajeev Nannapaneni: "Hopefully, I'll able to close something this year. Yes, hopefully I'll able to close something. I mean, I've been saying that for the last 2 years. I know I've not delivered. So I'll be honest with you."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revlimid volume sell-through | 75% of current allocation remains; expected to sell in June quarter with spill into September | Q1–Q2 FY24 |
| Agro inventory liquidation | ~INR100–110 crores to be liquidated in Kharif season | June and September quarters |
| R&D spending | More than INR300 crores, ~10% of revenues, 50% higher than last year | FY24 |
| Subsidiary growth | 15–20% growth led by new launches | FY24 |
| API business growth | 20–25% internal projection | FY24 |
| Domestic organic growth | 8–10% organic; 20–25% including acquisitions | FY24 |
| Product filings (key markets) | U.S.: 8–10, Canada: 8–10, Brazil: 8–10 | FY24 |
| FTF/niche filings | Another 8–10 targeted | FY24 |
| India product launches | About 10 products | FY24 |
| Agro revenue target | INR150-plus crores, targeting INR200 crores | FY24 |
| Base business profitability | INR100 crores quarterly PAT | Next 1–2 years |
| DASH front-end benefit | Own front end to start contributing | Next 1–2 years |
| Agri pipeline launches | 5–6 first-time indigenized products | Next 2 years |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Consolidated total revenue | ₹2,811.7 cr for FY23, growth of ~37.6% YoY |
| Consolidated net profit | ₹715.3 cr for FY23, versus ₹170 cr last year |
| Q4 consolidated net revenue | ₹926.9 cr, versus ₹610.6 cr in Q4 last year |
| Q4 consolidated profit | ₹275.8 cr, versus a loss of ₹50.5 cr in Q4 last year |
| Domestic business run rate | ~₹100 cr per quarter |
| Domestic business growth target | 8% to 10% organic, acquisition plus organic target 20% to 25% |
| API business growth projection | 20% to 25% for FY24 |
| Subsidiaries revenue contribution | ~₹555 cr gross, net ₹375 cr after deducting inter-company sales |
| Subsidiaries Q4 profit (PBT) | ₹28.97 cr |
| Canada subsidiary revenue | ~CAD 4 cr |
| Brazil subsidiary revenue | ~2.1 cr |
| Crop protection revenue | ₹40 cr in FY23, projection of ₹150-plus cr for FY24 |
| Agro inventory | ~₹100 cr to ₹110 cr |
| Revlimid allocation sold | ~25% of allocated quantity sold, 75% remaining |
| R&D spend | ~8% of revenue in FY23, guidance of ~10% for FY24 |
| Cash balance | ₹1,089 cr as of March 31, 2023 |
| Borrowings | ₹165 cr total, of which ₹95 cr is foreign bill discounting, ₹70 cr actual bank borrowing |
| Buyback | ~35 lakh shares bought back, equity reduced from ₹18.25 cr to ₹17.91 cr |
| One-time charge to raw material supplier | ₹50 cr for first-to-file success payment |
| Intangible asset purchase | ₹50 cr, goodwill on acquisition of DASH |